About
Editorial policy
The rules every page follows: primary sources only, no dosing or self-administration guidance, human review before publishing, corrections.
By the KPV Peptide editorial team · Last reviewed · Editorial review: pending
Sources
- Primary research indexed in PubMed, chemical databases (PubChem, FDA GSRS) and regulators’ own documents.
- No invented studies, outcomes, citations or safety findings. If a source cannot be verified, the claim is not published.
- Secondary reports are used only where no primary document is available, and are labelled as secondary.
What we will not publish
- Doses, schedules, protocols, routes, timing, or preparation or administration instructions for any person.
- Conversions of animal or cell-study amounts into human amounts.
- Statements that KPV is safe, effective or proven in humans, because no human data support them.
- Recommendations to combine (“stack”) KPV with other substances.
- Personal medical advice of any kind.
How findings are written
Study summaries name the model and report what was measured. Animal and cell findings are always labelled as such. Benefit-style questions are answered by tracing each claim to its evidence and grade (see benefits).
Review and approval
Every study record, regulatory source and owner link must be approved by a named reviewer before the production site will build. Material scientific or regulatory changes go through the same review. Pages display their review state.
Commercial independence
The site is owned by Peptide Titans, a seller of research peptides (see ownership). Owner links are limited to one labelled module per page, are marked as sponsored, and product links require compliance approval. Commercial considerations do not change how evidence is described.
Corrections and updates
Corrections can be sent to support@peptidetitans.com. The research corpus is re-verified at each review cycle, and each page shows its last-reviewed date.